NCT00053703View on ClinicalTrials.gov

Treatment of Early Onset Schizophrenia Spectrum Disorders (TEOSS)

PHASE4CompletedINTERVENTIONAL
Enrollment

116

Participants

Timeline

Start Date

February 28, 2002

Primary Completion Date

May 31, 2007

Study Completion Date

May 31, 2007

Conditions
Schizophrenia
Interventions
DRUG

Risperidone

oral risperidone 0.5mg to 6mg daily for up to 52 weeks

DRUG

Olanzapine (enrollment closed in this treatment)

oral olanzapine 5-20mg per day for up to 52 weeks

DRUG

Molindone

oral molindone from 10-140mg/daily for up to 52 weeks

Trial Locations (4)

27514

University of North Carolina, Chapel Hill

44106

University Hospitals of Cleveland, Cleveland

98195

University of Washington, Seattle

02155

Cambridge Health Alliance, Medford

All Listed Sponsors
collaborator

National Institute of Mental Health (NIMH)

NIH

lead

University of North Carolina, Chapel Hill

OTHER

NCT00053703 - Treatment of Early Onset Schizophrenia Spectrum Disorders (TEOSS) | Biotech Hunter | Biotech Hunter